logo
Twitter
Discord
Email
logo
Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc.

NASDAQ•PRAX
CEO: Mr. Marcio Silva De'Souza M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-10-16
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Contact Information
99 High Street, 30th Floor, Boston, MA, 02110, United States
617-300-8460
praxismedicines.com
Market Cap
$6.59B
P/E (TTM)
-25.1
37
Dividend Yield
--
52W High
$326.91
52W Low
$26.70
52W Range
95%
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00-100.00%
4-Quarter Trend

EPS

-$3.36+22.18%
4-Quarter Trend

FCF

-$64.74M+135.41%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Pipeline Milestones Achieved Ulixacaltamide Phase 3 results positive; FDA pre-NDA meeting set for Q4 2025; Relutrigine received Breakthrough Therapy Designation.
Major Financing Completed Company closed October 2025 public offering, raising approximately $567.0 M in net proceeds to extend operational runway.
R&D Investment Surge Nine Months R&D expenses increased $93.5 M USD, driven by significant spend increases across Cerebrum platform programs.
Cash Position Strong Cash, cash equivalents, and marketable securities totaled $389.2 M USD as of September 30, 2025, supporting near-term plans.

Risk Factors

Widening Net Loss Nine Months Net Loss reached $214.4 M USD, representing a $90.2 M increase compared to the prior nine-month period.
High Operating Burn Operating cash use increased substantially; company expects continued significant operating losses for the foreseeable future.
Future Capital Dependency Future viability depends on raising substantial additional capital, as current funding is projected to last only into 2028.
Collaboration Revenue Loss Collaboration revenue dropped $1.1 M USD NME as UCB exercised its in-license option, eliminating future research obligations.

Outlook

Ulixacaltamide Regulatory Path FDA Type B pre-NDA meeting for ulixacaltamide is scheduled to occur during the fourth quarter of 2025.
Vormatrigine Data Readout Expect topline results for the POWER1 efficacy study for vormatrigine in the first half of calendar year 2026.
Relutrigine Interim Analysis Planning an interim analysis of the second cohort for the ongoing EMBOLD study during the fourth quarter of 2025.
Preclinical Candidate Nomination Anticipate nominating development candidates for PRAX-080, PRAX-090, and PRAX-100 in the first half of 2026.

Peer Comparison

Revenue (TTM)

Nektar TherapeuticsNKTR
$62.60M
-32.8%
Immunome, Inc.IMNM
$9.68M
-4.4%
Relay Therapeutics, Inc.RLAY
$8.36M
-16.5%

Gross Margin (Latest Quarter)

Dianthus Therapeutics, Inc.DNTH
100.0%
+0.0pp
Oculis Holding AGOCS
100.0%
+0.0pp
Nektar TherapeuticsNKTR
100.0%
+18.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRAX$6.59B-25.1-66.9%0.1%
IMNM$2.37B-10.2-87.2%1.3%
DNTH$1.89B-15.7-33.0%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 27, 2026
|
EPS:-$3.00
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-3.36+22.2%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 4, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-3.31+90.2%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 2, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-3.29+15.8%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 28, 2025|
    Revenue: $8.55M+249.5%
    |
    EPS: $-10.21+45.4%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $302.00K-35.5%
    |
    EPS: $-2.75+1.1%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $357.00K-54.3%
    |
    EPS: $-1.74-76.4%
    Meet

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $431.00K-36.9%
    |
    EPS: $-2.84-72.7%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 5, 2024|
    Revenue: $2.45M+0.0%
    |
    EPS: $-18.69+73.0%
    Miss